RD133

DRUG2 trials

Sponsors

Tongji Hospital, The First Affiliated Hospital with Nanjing Medical University

Conditions

CancerSolid Tumor

Early Phase 1

Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

RecruitingNCT05141253

Tongji HospitalCancer

Start: 2022-01-12End: 2036-11-01Target: 24Updated: 2022-04-27

An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

RecruitingNCT05166070

The First Affiliated Hospital with Nanjing Medical UniversitySolid Tumor

Start: 2022-01-01End: 2037-01-01Target: 24Updated: 2021-12-21

Related Papers

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Advanced Science2026-08-10

Abstract 4277: AQP3 NOT gating mitigates lethal on-target off-tumor pulmonary toxicity of MSLN-directed CAR-T cells in ovarian cancer

Cancer Research2026-04-03

Abstract 3997: PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer

Cancer Research2024-03-22